Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · IEX Real-Time Price · USD
6.56
+0.40 (6.49%)
At close: Mar 28, 2024, 4:00 PM
6.78
+0.22 (3.35%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Terns Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
001000
Gross Profit
001000
Selling, General & Admin
39.0622.4119.5598.663.9
Research & Development
63.539.6231.3128.0361.5314.55
Operating Expenses
102.5662.0350.8637.0370.218.46
Operating Income
-102.56-62.03-49.86-37.03-70.2-18.46
Other Expense / Income
-12.59-2.04-0.212.22-1.57-0.68
Pretax Income
-89.97-59.99-49.65-39.24-68.63-17.78
Income Tax
0.240.360.510.81-0.02-0.07
Net Income
-90.21-60.35-50.16-40.05-68.61-17.71
Preferred Dividends
000-10.700
Net Income Common
-90.21-60.35-50.16-29.35-68.61-17.71
Shares Outstanding (Basic)
713623000
Shares Outstanding (Diluted)
713623000
Shares Change
97.76%58.69%7862.47%55.60%145.81%-
EPS (Basic)
-1.27-1.67-2.21-102.93-374.39-237.56
EPS (Diluted)
-1.27-1.67-2.21-102.93-374.39-237.56
Free Cash Flow
-67.44-49.38-42.17-30.39-67.12-18.32
Free Cash Flow Per Share
-0.95-1.37-1.86-106.58-366.26-245.66
Gross Margin
--100.00%---
Operating Margin
---4986.00%---
Profit Margin
---5015.80%---
Free Cash Flow Margin
---4216.70%---
EBITDA
-89.09-58.96-49.14-38.85-68.44-17.71
EBITDA Margin
---4913.80%---
Depreciation & Amortization
0.881.030.510.390.20.07
EBIT
-89.97-59.99-49.65-39.24-68.63-17.78
EBIT Margin
---4965.00%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).